Cerecor Inc (NASDAQ:CERC) major shareholder Armistice Capital Master Fund purchased 49,100 shares of the stock in a transaction on Tuesday, November 20th. The shares were purchased at an average price of $3.61 per share, with a total value of $177,251.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Thursday, November 15th, Armistice Capital Master Fund purchased 31,314 shares of Cerecor stock. The shares were purchased at an average price of $3.85 per share, with a total value of $120,558.90.
  • On Wednesday, October 31st, Armistice Capital Master Fund purchased 5,986 shares of Cerecor stock. The shares were purchased at an average price of $3.92 per share, with a total value of $23,465.12.
  • On Monday, October 29th, Armistice Capital Master Fund purchased 107,800 shares of Cerecor stock. The shares were purchased at an average price of $3.95 per share, with a total value of $425,810.00.
  • On Wednesday, October 24th, Armistice Capital Master Fund purchased 125,800 shares of Cerecor stock. The shares were purchased at an average price of $4.13 per share, with a total value of $519,554.00.
  • On Tuesday, October 9th, Armistice Capital Master Fund purchased 29,600 shares of Cerecor stock. The shares were purchased at an average price of $4.34 per share, with a total value of $128,464.00.
  • On Thursday, September 27th, Armistice Capital Master Fund purchased 20,400 shares of Cerecor stock. The shares were purchased at an average price of $4.64 per share, with a total value of $94,656.00.

Cerecor stock traded down $0.02 during mid-day trading on Tuesday, hitting $3.57. 86,900 shares of the stock were exchanged, compared to its average volume of 166,229. The firm has a market cap of $153.02 million, a price-to-earnings ratio of 8.50 and a beta of 1.48. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.70 and a current ratio of 0.74. Cerecor Inc has a 12 month low of $1.17 and a 12 month high of $5.74.

Several research analysts have issued reports on the stock. TheStreet upgraded shares of Cerecor from a “d” rating to a “c” rating in a report on Monday, November 12th. ValuEngine upgraded shares of Cerecor from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

Several large investors have recently added to or reduced their stakes in CERC. Cambridge Investment Research Advisors Inc. purchased a new stake in Cerecor in the 3rd quarter worth approximately $169,000. BlackRock Inc. raised its holdings in shares of Cerecor by 630.4% during the 2nd quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock valued at $120,000 after purchasing an additional 23,752 shares in the last quarter. Spark Investment Management LLC bought a new position in shares of Cerecor during the 2nd quarter valued at $288,000. Finally, Northern Trust Corp raised its holdings in shares of Cerecor by 182.0% during the 1st quarter. Northern Trust Corp now owns 31,506 shares of the company’s stock valued at $135,000 after purchasing an additional 20,333 shares in the last quarter. Institutional investors own 41.66% of the company’s stock.

WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/11/20/cerecor-inc-cerc-major-shareholder-buys-177251-00-in-stock.html.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

Featured Story: Why do earnings reports matter?

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.